ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Cara Therapeutics Initiates Second Pruritus Phase 2 Trial of Peptelligence®
June 28, 2019Enteris BioPharma congratulates Cara Therapeutics on the successful initiation of its Phase 2 clinical trial of Oral KORSUVA™ (CR845/difelikefalin) for the treatment of pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC).
Pharma Sources Insight January 2025
